Can long-term use of imatinib maintain survival?

Imatinib/Gleevec (Imatinib) is one of the important targeted drugs for the treatment of diseases such as chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST). Since its launch, it has been considered a major breakthrough in anti-cancer treatment. For many CML patients, long-term persistence in taking imatinib can significantly prolong survival time, and even allow some patients to reach a level close to normal life span. Its mechanism is to prevent leukemia cell proliferation by inhibiting the activity of BCR-ABL tyrosine kinase. In most patients with chronic phase CML, long-term regular medication can control the disease well, and it is not uncommon for remission to be maintained for more than 10 years. Multiple overseas clinical practices have shown that patients who continue to use imatinib have a very low risk of disease progression if they are in the molecular remission or deep remission stage, and their survival curve is significantly better than that of patients with traditional therapies who do not use targeted drugs.

Nevertheless, long-term use is not completely risk-free. Some patients may develop drug resistance or have adverse reactions to imatinib, such as abnormal liver function, rash, edema, etc., which may affect their quality of life or require a change of treatment plan. However, in most cases, these side effects can be alleviated through dose adjustment or supportive care. Long-term medication requires regular review of blood count, liver and kidney function, gene mutation testing, etc. to determine the effect of treatment and whether the drug strategy needs to be adjusted. Imatinib is not a one-time solution, but needs to be combined with the dynamic management of the patient's condition. For some patients who meet certain remission criteria, doctors may also consider a "try-off" strategy, but this requires strict monitoring to ensure that the risk of relapse is low.

Therefore, long-term use of imatinib has definite significance in prolonging the survival of CML and GIST patients. It not only improves the quality of life, but also reshapes the treatment expectations of chronic tumors. The key is to adhere to regular medication, regularly monitor efficacy, and follow professional guidance to maximize clinical benefits in long-term treatment.

Reference materials:https://www.gleevec.com/